Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Cancer vaccine induces potent T cell responses — but is it enough?

Tumour-associated antigens are an attractive therapeutic target in immuno-oncology. Here, the exploratory analyses of T cell responses and preliminary clinical outcomes of the Lipo-MERIT trial of a melanoma vaccine are discussed in the context of prior efforts to harness the immunogenicity of such antigens for antitumour immunity.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Summary of the FixVac approach used by Sahin et al. in the Lipo-MERIT trial5.


  1. Andersen, R. S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642–1650 (2012).

    CAS  Article  Google Scholar 

  2. Barrow, C. et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12, 764–771 (2006).

    CAS  Article  Google Scholar 

  3. Jäger, E. et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA 97, 4760–4765 (2000).

    Article  Google Scholar 

  4. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915 (2004).

    CAS  Article  Google Scholar 

  5. Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107–112 (2020).

    CAS  Article  Google Scholar 

  6. Betof Warner, A. et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J. Clin. Oncol. 38, 1655–1663 (2020).

    CAS  Article  Google Scholar 

  7. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).

    Article  Google Scholar 

  8. Slingluff, C. L. et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin. Cancer Res. 19, 4228–4238 (2013).

    CAS  Article  Google Scholar 

  9. Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, (2020).

  10. Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9–16 (2018).

    CAS  Article  Google Scholar 

Download references


The work of the authors is supported by the NIH National Cancer institute SPORE in Skin Cancer grant P50 CA-121973.

Author information

Authors and Affiliations


Corresponding author

Correspondence to John M. Kirkwood.

Ethics declarations

Competing interests

J.M.K. has received grants and personal fees for consultancy from Amgen, Bristol-Myers Squibb, Checkmate and Novartis, and grants from Castle Biosciences, Immunocore and Iovance. A.R. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rohatgi, A., Kirkwood, J.M. Cancer vaccine induces potent T cell responses — but is it enough?. Nat Rev Clin Oncol 17, 721–722 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer